Comparison of Two Photobiomodulation Systems for Facial Nerve Dysfunction Following TMJ Surgery
Comparison of the Clinical Effectiveness of Two Photobiomodulation Systems for Facial Nerve Dysfunction Following Temporomandibular Joint Surgery
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This prospective, randomized, parallel-group clinical trial was conducted in patients who developed postoperative facial nerve dysfunction following open temporomandibular joint surgery. Eligible participants were randomly allocated in a 1:1 ratio to one of two active photobiomodulation treatment groups using a computer-generated block randomization sequence.
Participants assigned to the GRR Laser group received extraoral transcutaneous photobiomodulation using a dual-wavelength 650-nm and 904-nm laser/LED system. Participants assigned to the SiroLaser Advance Plus group received extraoral transcutaneous photobiomodulation using a 660-nm continuous-wave diode laser. In both groups, irradiation was applied along the anatomical projection of the clinically affected facial nerve branches on the operated side.
Photobiomodulation treatment was initiated on the first postoperative day. Treatment was administered daily during the first five postoperative days and every other day thereafter, for a total of 15 treatment sessions. Each treatment session lasted approximately 10 minutes.
Facial nerve function was evaluated on postoperative days 5, 7, 10, 30, and 60. Clinical assessments included the House-Brackmann Grading System and the Sunnybrook Facial Grading System. Patient-reported functional status and quality of life were assessed using the Facial Clinimetric Evaluation (FaCE) Scale. The first standardized outcome assessment was performed on postoperative day 5; therefore, this assessment represented the first standardized postoperative evaluation rather than a pretreatment baseline.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ankara
-
Ankara, Ankara, Turquie (Türkiye)
- Ankara University Faculty of Dentistry
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients who underwent open temporomandibular joint surgery.
- Presence of clinically confirmed postoperative facial nerve dysfunction.
- Willingness to comply with the follow-up protocol and attend scheduled follow-up visits.
- Provision of written informed consent.
Exclusion Criteria:
- Pre-existing facial nerve paralysis or facial nerve dysfunction before surgery.
- History of central neurological disease.
- Previous surgery involving the facial nerve.
- History of head and neck malignancy and/or chemotherapy or radiotherapy that could potentially affect facial nerve function.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: SiroLaser Advance Plus Group
Participants received photobiomodulation using the SiroLaser Advance Plus system.
|
Extraoral transcutaneous photobiomodulation was delivered using the SiroLaser Advance Plus system in SoftLase mode.
Irradiation was provided using a 660-nm continuous-wave diode laser with an output power of 25 mW through an 8-mm fiber-optic tip.
Treatment was applied along the anatomical projection of the clinically affected facial nerve branches.
Treatment began on the first postoperative day and consisted of 15 sessions using the same treatment schedule as the GRR Laser group.
|
|
Expérimental: GRR Laser Group
Participants received photobiomodulation using the GRR Laser system.
|
Extraoral transcutaneous photobiomodulation was delivered using the GRR Laser system, a dual-wavelength 650-nm and 904-nm laser/LED system.
Treatment was applied along the anatomical projection of the clinically affected facial nerve branches.
Treatment began on the first postoperative day and consisted of 15 sessions, administered daily during the first 5 postoperative days and every other day thereafter.
Each session lasted approximately 10 minutes.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Sunnybrook Facial Grading System Score
Délai: From postoperative day 5 to postoperative day 60
|
The Sunnybrook Facial Grading System was used to assess facial nerve function based on resting symmetry, voluntary facial movement, and synkinesis.
The composite score ranges from 0 to 100, with higher scores indicating better facial nerve function.
The change score was calculated as the postoperative day 60 score minus the postoperative day 5 score.
|
From postoperative day 5 to postoperative day 60
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
House-Brackmann Grading System
Délai: Postoperative days 5, 7, 10, 30, and 60
|
Facial nerve function was graded using the House-Brackmann Grading System, which classifies facial nerve function from Grade I (normal function) to Grade VI (complete paralysis), with higher grades indicating greater dysfunction.
|
Postoperative days 5, 7, 10, 30, and 60
|
|
Facial Clinimetric Evaluation (FaCE) Scale
Délai: Postoperative days 5, 7, 10, 30, and 60
|
The FaCE Scale is a 15-item patient-reported measure assessing facial movement, facial comfort, oral function, eye comfort, lacrimal control, and social function.
Total scores are transformed to a 0-100 scale, with higher scores indicating better facial function and quality of life.
|
Postoperative days 5, 7, 10, 30, and 60
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Mehmet Emre Yurttutan, DDS, PhD, Ankara University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- AU-TMJ-PBM-2022
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .